SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants
Archana Panikkar(QIMR Berghofer Medical Research Institute), Corey Smith(QIMR Berghofer Medical Research Institute), George Ambalathingal(The University of Queensland), Sweera Rehan(QIMR Berghofer Medical Research Institute), Katherine Matthews, Sriganesh Srihari(QIMR Berghofer Medical Research Institute), Srividhya Swaminathan(The University of Queensland), Matthew D. Solomon(Sutter Health), Kirsty R. Short(The University of Queensland), Katie E. Lineburg(QIMR Berghofer Medical Research Institute), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Shannon E. Best(QIMR Berghofer Medical Research Institute), Keng Yih Chew(Australian Research Council), Laëtitia Le Texier(QIMR Berghofer Medical Research Institute), Leone Beagley, Jyothy Raju(QIMR Berghofer Medical Research Institute), Pauline Crooks(QIMR Berghofer Medical Research Institute)
Cited by 21
Related Papers
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
|The Journal of Experimental Medicine|1992|391
Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
|Proceedings of the National Academy of Sciences|1999|332
Back to the Future: Lessons Learned From the 1918 Influenza Pandemic
|Frontiers in Cellular and Infection Microbiology|2018|282
An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease.
|The Journal of Experimental Medicine|1994|276
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272